BOSTON (AP) _ Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $6.2 million in its third quarter.
The Boston-based company said it had a loss of 11 cents per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 15 cents per share.
The biopharmaceutical company posted revenue of $8.3 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $6.2 million.
The company's shares closed at $4.38. A year ago, they were trading at $4.92.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PIRS at https://www.zacks.com/ap/PIRS